Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2015 June;67(3) > Minerva Ginecologica 2015 June;67(3):249-55

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as
Share

 

REVIEWS   

Minerva Ginecologica 2015 June;67(3):249-55

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Hormone replacement therapy: who should be treated?

Gambacciani M. 1, Levancini M. 1, 2

1 Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy; 2 Department of Obstetrics and Gynecology, Clinica Alemana, Universidad Del Desarrollo Santiago, Chile


PDF


The last decade has been characterized by a careful review of the risks and benefits of hormone replacement therapy (HRT). Various types and doses as well as different combinations, may offer different advantages in different groups of women. Women with premature or early menopause may benefit from HRT, at least until the age at which natural menopause usually occurs. The most favorable benefits of HRT is in symptomatic younger women (50-59 years) within 10 years since menopause. Beside the effect on symptoms, these patients have additional benefits such as reduction in cardiovascular disease (CVD), osteoporotic fractures, and overall mortality. In older women low-dose or ultra-low-dose HRT may have a better safety profile than standard dose oral combinations. Currently, available evidence does not support the use of HRT for the sole osteoporosis or CVD and cognition decline prevention.

top of page